Silka Antifungal (Terbinafine Hydrochloride)
Brand Names: Silka Antifungal
Methodology & AI Transparency ⓘ
Silka Antifungal (Terbinafine Hydrochloride) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Terbinafine Hydrochloride (cross-referenced at /meds/terbinafine-hydrochloride) and registered by Genomma Lab USA, Inc., Silka Antifungal operates as a over-the-counter branded azole antifungal therapy (RxNorm 1739221; NDC 50066-080, 50066-085).
- 2 Real-world patient consensus: Commercial Silka Antifungal monograph (1 g/100mL Liquid) cross-indexed with generic Terbinafine Hydrochloride for therapeutic equivalence review.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $28.76 cash mean against $76.21 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Silka Antifungal (Terbinafine Hydrochloride): pruritus (5.1%), diarrhea (9.4%), nausea (7.7%).
Ask our AI Specialists anything about Silka Antifungal (Terbinafine Hydrochloride)
Silka Antifungal (Terbinafine Hydrochloride) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Terbinafine Hydrochloride (cross-referenced at /meds/terbinafine-hydrochloride) and registered by Genomma Lab USA, Inc., Silka Antifungal operates as a over-the-counter branded azole antifungal therapy (RxNorm 1739221; NDC 50066-080, 50066-085). Under 2025-07-02 FDA labeling for 1 g/100mL Liquid; 250mg Tablet, Uses cures most athlete's foot (tinea pedis) cures most jock itch (tinea cruris) and ringworm (tinea corporis) relieves.
Bioactive Terbinafine Hydrochloride within Silka Antifungal governs azole antifungal target modulation with class-characteristic hepatorenal disposition. Commercialized across 1 g/100mL Liquid; 250mg Tablet (registered by Genomma Lab USA, Inc., SPL 2025-07-02), Silka Antifungal combines branded dosage-form consistency (NDC 50066-080, 50066-085) with transparent cash-pay comparisons spanning $28.76 to $76.21.
Following administration (1 g/100mL Liquid), Silka Antifungal (Terbinafine Hydrochloride) achieves Approximately 65% to 77% enteral uptake across labeled Silka Antifungal (Terbinafine Hydrochloride) strengths bioavailability and maximum serum exposure occurs 2–4 hours after silka antifungal (terbinafine hydrochloride) dosing onset, governed by a Steady-state plasma equilibrium reached over 6–15 hour t½ intervals for Silka Antifungal (Terbinafine Hydrochloride) terminal half-life through predominantly hepatic biotransformation with renal elimination of polar silka antifungal (terbinafine hydrochloride) conjugates.
Before initiating Silka Antifungal (Terbinafine Hydrochloride) at 1 g/100mL Liquid, clinical safety checklists rule out previous anaphylactoid or exfoliative reaction attributed to silka antifungal (terbinafine hydrochloride); clinical scenarios where azole antifungal exposure from silka antifungal (terbinafine hydrochloride) poses unacceptable risk. Logged tolerability patterns center on diarrhea (9.4% of reports), nausea (7.7% of reports), headache (6.2% of reports).
Verify medication reconciliation lists so Silka Antifungal (Terbinafine Hydrochloride) is not inadvertently duplicated with another azole antifungal.
Unstandardized herbal extracts may interact pharmacodynamically with Silka Antifungal (Terbinafine Hydrochloride) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Silka Antifungal (Terbinafine Hydrochloride)
- Clinical scenarios where azole antifungal exposure from Silka Antifungal (Terbinafine Hydrochloride) poses unacceptable risk
Logged Side-Effect Incidence (11 Reports)
Silka Antifungal (Terbinafine Hydrochloride) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Silka Antifungal (Terbinafine Hydrochloride))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Skin-applied Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in: What a 1,655-Participant Study Found Applied to the skin efinaconazole 10% showed favorable efficacy/safety in White, Asian, and Black participants with mild-to-moderate onychomycosis. Journal of drugs in dermatology : JDD • 2026-01-01 • Phase III Randomized Trial | N = 1,655 | 96/100 | PMID 41493257 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Naftifine Hydrochloride 2% Gel in Interdigital Tinea Naftifine 2% gel was efficacious and safe for the treatment of mild to moderate interdigital tinea pedis. Clinical drug investigation • 2023-07-15 • Phase III Randomized Trial | N = 112 | 88/100 | PMID 37462803 ↗ |
| New Insights on Phase 3 study evaluating the safety and real-world benefits of oteseconazole in: What a 219-Participant Study Found In participants with recurrent vulvovaginal candidiasis, oteseconazole was safe and efficacious in the treatment and prevention of recurrent acute vulvovaginal candidiasis episodes and was noninferior to vulvovaginal... American journal of obstetrics and gynecology • 2022-12-15 • Phase III Randomized Trial | N = 219 | 88/100 | PMID 35863457 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Rezafungin Versus Caspofungin for the Treatment of Rezafungin demonstrated similar real-world benefits and safety to caspofungin in the ReSTORE China cohort. Mycoses • 2025-11-15 • Phase III Randomized Trial | N = 58 | 88/100 | PMID 41194465 ↗ |
| Can This Approach Help? Inside the Latest Research on Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Ibrexafungerp provides a promising safe and efficacious oral treatment that mechanistically differs from current azole treatment options for acute VVC. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2022-06-10 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34467969 ↗ |
Silka Antifungal (Terbinafine Hydrochloride) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2813/unit (~$8.44/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $76.21 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $28.76 / mo | View logs ↓ |
Silka Antifungal (Terbinafine Hydrochloride) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Silka Antifungal (Terbinafine Hydrochloride) RxNorm Concept ID | 1739221 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2813 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $76.21 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $28.76 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Silka Antifungal (Terbinafine Hydrochloride) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Silka Antifungal (Terbinafine Hydrochloride) (azole antifungal) monograph synthesizing RxNorm 1739221, openFDA FAERS signals, and $28.76–$76.21 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Silka Antifungal (Terbinafine Hydrochloride) community threads and patient logs by age, biological sex, dosage, and treatment duration.